Mutual of America Capital Management LLC Acquires Shares of 48,763 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Key Points

• Mutual of America Capital Management acquired 48,763 shares of Xenon Pharmaceuticals worth approximately $1,636,000, representing a 0.06% ownership stake in the company.
• Xenon Pharmaceuticals reported earnings per share of ($0.83) for the last quarter, surpassing analysts' expectations of ($0.90) by $0.07, with a revenue of $7.50 million.
• Analysts have downgraded their price targets for Xenon Pharmaceuticals, with the average target now at $54.33, reflecting a consensus rating of "Moderate Buy."

Mutual of America Capital Management LLC acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 48,763 shares of the biopharmaceutical company's stock, valued at approximately $1,636,000. Mutual of America Capital Management LLC owned approximately 0.06% of Xenon Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. GF Fund Management CO. LTD. boosted its holdings in shares of Xenon Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company's stock valued at $65,000 after acquiring an additional 351 shares during the last quarter. Natixis Advisors LLC boosted its holdings in shares of Xenon Pharmaceuticals by 1.9% during the 1st quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company's stock valued at $806,000 after acquiring an additional 456 shares during the last quarter. Occudo Quantitative Strategies LP boosted its holdings in shares of Xenon Pharmaceuticals by 5.8% during the 4th quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company's stock valued at $448,000 after acquiring an additional 630 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Xenon Pharmaceuticals by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock valued at $2,726,000 after acquiring an additional 720 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its holdings in shares of Xenon Pharmaceuticals by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 193,004 shares of the biopharmaceutical company's stock valued at $7,566,000 after acquiring an additional 1,346 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock opened at $33.43 on Friday. The company has a market capitalization of $2.57 billion, a PE ratio of -10.35 and a beta of 1.16. The company has a 50-day simple moving average of $31.98 and a two-hundred day simple moving average of $34.13. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.07. The company had revenue of $7.50 million for the quarter, compared to analyst estimates of $1.64 million. During the same quarter last year, the company earned ($0.62) EPS. On average, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Needham & Company LLC dropped their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. Evercore ISI started coverage on shares of Xenon Pharmaceuticals in a report on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price objective on the stock. Royal Bank Of Canada dropped their price objective on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Finally, Wells Fargo & Company dropped their price objective on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $54.33.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.